Form 4: Soleno Therapeutics SVP Exercises Options and Sells Shares, Adjusts Holdings Under 10b5-1 Plan

Patricia C. Hirano, Senior Vice President of Regulatory Affairs at Soleno Therapeutics Inc., exercised stock options and sold an equal number of shares, while also reporting a significant adjustment to her beneficial ownership.

Summary

• Patricia C. Hirano, Senior Vice President of Regulatory Affairs at Soleno Therapeutics Inc. (SLNO), executed stock transactions on June 24, 2025.
• She acquired 266 shares of common stock by exercising employee stock options at a price of $44.25 per share.
• Concurrently, she sold 266 shares of common stock at a price of $84.25 per share.
• Both the option exercise and the subsequent sale were conducted pursuant to a Rule 10b5-1 trading plan, which was established on September 13, 2024.
• Following these transactions, her direct beneficial ownership of common stock stands at 17,036 shares.
• Notably, her total reported beneficial ownership was decreased by 10,000 shares as a result of an internal review of her holdings.
• The employee stock options that were exercised were fully vested and exercisable prior to the transaction.

Sentiment

Score: 4

Explanation: The sentiment is slightly negative due to the significant reduction of 10,000 shares in beneficial ownership, which is not directly tied to the exercise-and-sell transaction and suggests a re-evaluation or correction of previously reported holdings. While the exercise and sale were profitable for the insider and conducted under a 10b5-1 plan, the overall net decrease in reported holdings is a notable negative.

Positives

• The reporting person realized a profit from the sale, selling shares at $84.25 after exercising options at $44.25, resulting in a gain of $40.00 per share on the 266 shares.
• The transactions were executed under a pre-arranged Rule 10b5-1 trading plan, which indicates a structured and pre-planned approach to insider equity management.

Negatives

• The reporting person's total beneficial ownership decreased by 10,000 shares due to an internal review, representing a significant reduction in her reported stake in the company.
• The sale of shares by an insider, even under a 10b5-1 plan, can sometimes be perceived by the market as a reduction in direct alignment with shareholder interests.

Future Outlook

NA

Industry Context

This Form 4 filing details routine insider equity transactions, common across all industries for executives managing their compensation and equity holdings. It does not provide specific insights into broader industry trends for the biotechnology or pharmaceutical sector where Soleno Therapeutics operates, beyond illustrating a standard component of executive compensation.

Related Party Transactions

• The transactions detailed in this Form 4, involving an officer of Soleno Therapeutics Inc. exercising stock options and selling common stock, are inherently related-party transactions as they involve an insider's dealings with company securities.

Stakeholder Impact

• Shareholders may interpret the insider's sale and the significant reduction in reported beneficial ownership as a signal, potentially influencing investor sentiment regarding management's confidence or personal financial planning.
• Employees with similar equity compensation plans may view the exercise of stock options as a standard benefit realization.

Key Dates

Recommendation

Keywords

SOLENO THERAPEUTICS INC, SLNO, SEC Form 4, Insider Trading, Stock Option Exercise, Stock Sale, Rule 10b5-1 Plan, Beneficial Ownership, Corporate Officer, Regulatory Affairs, Equity Transaction